Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced preliminary results of a Phase 1 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary results as of April 2009 showed that OGX-427 was well tolerated as a monotherapy. In addition, OGX-427 demonstrated declines in circulating tumor cells at all doses evaluated as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells and tumor markers both suggest single-agent activity warranting further clinical investigation.

The Phase 1 trial has evaluated 41 patients with a variety of cancers to date; enrollment is ongoing. The first phase of the study evaluated increasing doses of OGX-427 as a single agent up to 1000 mg. A maximum tolerated dose was not identified up to and including the 1000-mg dose of OGX-427 monotherapy. Subsequently, as defined by the protocol, an 800-mg dose of OGX-427 in combination with docetaxel was evaluated, to be followed by a 1000-mg dose of OGX-427 plus docetaxel. OGX-427 is administered as three loading doses within the first 9 days and then continued weekly, with three weeks defined as a treatment cycle, until disease progression or toxicity. In those groups receiving OGX-427 in combination with docetaxel, 75mg/M(2) docetaxel was administered on Day 1 of every 3-week cycle starting after completion of the OGX-427 loading doses.

Safety Results

Patients enrolled had a diagnosis of breast, ovarian, prostate or non-small cell lung cancer and most had failed multiple prior chemotherapy treatments. A median of 2 cycles (range of 1-8 cycles) was administered with the following safety results for OGX-427 as monotherapy:

    -   Criteria for a maximum tolerated dose were 
'/>"/>
SOURCE  OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... SAN DIEGO , May 20, 2013  Dr. ... the field of nucleic acid research, recently launched a ... Zone In with Zon ( zon.trilinkbiotech.com ), focuses on ... posts include interviews with industry thought leaders, discussions of ... publications and more. Dr. Zon (PhD ...
(Date:5/20/2013)... Pacific Biomarkers and Clinigene International are set to unveil ... the 2013 AAPS/ National Biotechnology Conference May ... Marina , San Diego, CA. ... with company representatives at their collaborative seminar, "Biosimilarity, Immunogenicity ... from 1-2 p.m. in the conference,s Spinnaker Room. ...
(Date:5/20/2013)... NY (PRWEB) May 20, 2013 With bed ... Products said that although bed bugs need to be eliminated, ... will not compromise a person's health. And so to help ... how to get rid of bed bugs without ... non-pesticide bed bug spray it called Bed Bug Bully. , ...
(Date:5/20/2013)... , Md. and BALTIMORE , ... (BHI), a regional private-public partnership focusing on ... early-stage funding in Central Maryland ... Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) for ... National Heart, Lung and Blood Institute ...
Breaking Biology Technology:Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4
... ST. LOUIS, June 2 SAFC Hitech(TM), a ... Group (Nasdaq: SIAL ),today announced the introduction ... cost-efficient migration path to controlled precursor delivery,for larger ... combined,with increased safety controls., The OM700 offers ...
... expertise, SAN DIEGO, June 2 Trius ... to its Board of Directors. Truex is,the founder, ... as President and CEO of Peninsula Pharmaceuticals where ... $21000000 from a key,strategic partner) and negotiated both ...
... Further ... Clinical Development of tgAAC94, BOSTON and SEATTLE, May 30 ... release earlier today, entitled,"Targeted Genetics Reports Additional Data From Inflammatory ... study of tgAAC94 in patients with inflammatory arthritis. Pervin,Anklesaria, Ph.D., ...
Cached Biology Technology:SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 2SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 3Trius Appoints Paul Truex to Board of Directors 2Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings 2Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings 3
(Date:5/20/2013)... A novel vaccine study from South Dakota State University ... unveiled at the American Association of Pharmaceutical Scientists, (AAPS) ... May 20 - Wednesday, May 22 at the Sheraton ... goal of a vaccine is to stimulate the immune ... disease", explained Dr. Hemachand Tummala, assistant professor of Pharmaceutical ...
(Date:5/20/2013)... of Bristol and published online today in the ... the brain and inner ear developed in dinosaurs. ... together with Tom Hbner from the Niederschsische Landesmuseum in ... old dinosaurs. , The two palaeontologists studied different fossils ... very young (juvenile) individual of approximately three years ...
(Date:5/20/2013)... Boulder, Colo., USA New Geology ... 16 May 2013 cover a wide swath of ... tectonics, oceanography, geophysics, and paleobotany. Locations studied include ... mine at Alpi Apuane, Italy; Ukraine; Mars; and ... , 1. Rubies, jadeite, and plate tectonics;, ...
Breaking Biology News(10 mins):Germ-fighting vaccine system makes great strides in delivery 2Fossil brain teaser 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 3New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 4New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 5New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 6New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 7New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 8New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 9New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 10New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 11
... for the annual infectious diseases meeting of the American ... 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ... Place Convention Center in Chicago, Illinois. ... new information on clinical and basic research in infectious ...
... of a natural body chemical may allow doctors to reduce ... of critically ill patients. "Infection is a common and ... ways to improve the outcomes of sick, elderly patients and, ... Heyland, a professor of Medicine at Queen,s, director of the ...
... the U.S. first responder community,s need for documentary standards ... Institute of Standards and Technology (NIST) Law Enforcement Standards ... to first responders as part of a pilot project ... will help OLES gauge whom needs access to standards ...
Cached Biology News:Finding could reduce antibiotic use in critically ill patients 2It's your standard pilot project: NIST to offer documentary standards to first responders 2
...
... (rEK) is a highly purified preparation of ... serine protease which recognizes the identical cleavage ... has similar enzymatic activity. Novagen&'s enzyme is ... purified to yield the highest activity available, ...
... Affinity purified polyclonal antibody to the ... Goat. Isolated from a serum pool ... Salmonella. This antibody is broadly reactive ... from ATCC. It has excellent specificity ...
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
Biology Products: